• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    US CAR T Cell Therapy Market

    ID: MRFR/Pharma/11329-HCR
    100 Pages
    Rahul Gotadki
    September 2025

    US Car T Cell Therapy Market Research Report By Therapeutic Area (Oncology, Autoimmune Diseases, Infectious Diseases), By Cell Source (Autologous, Allogeneic, Gene-Edited), By Indication (Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma, Multiple Myeloma) and By End User (Hospitals, Research Institutes, Cancer Treatment Centers) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    US CAR T Cell Therapy Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    US CAR T Cell Therapy Market Summary

    The US Car T Cell Therapy market is projected to grow from 2 USD Billion in 2024 to 10 USD Billion by 2035, reflecting a robust CAGR of 15.76%.

    Key Market Trends & Highlights

    US Car T Cell Therapy Key Trends and Highlights

    • The market valuation is expected to reach 10 USD Billion by 2035, indicating substantial growth opportunities.
    • From 2025 to 2035, the market is anticipated to expand at a compound annual growth rate of 15.76%.
    • In 2024, the market is valued at 2 USD Billion, laying a solid foundation for future expansion.
    • Growing adoption of CAR T Cell Therapy due to increasing prevalence of cancer is a major market driver.

    Market Size & Forecast

    2024 Market Size 2 (USD Billion)
    2035 Market Size 10 (USD Billion)
    CAGR (2025-2035) 15.76%

    Major Players

    Legend Biotech, Sana Biotechnology, Bristol Myers Squibb, Novartis, Celgene, Kite Pharma, Fate Therapeutics, Gilead Sciences, Adaptimmune, CureVac, CART T Cell Therapies, Amgen, Bioxcel Therapeutics, Juno Therapeutics, Celyad Oncology

    US CAR T Cell Therapy Market Trends

    The US Car T Cell Therapy Market is experiencing significant growth driven by several key market drivers. The increasing incidence of various types of cancers, such as hematologic malignancies, has accelerated the demand for advanced treatments like CAR T cell therapy. Major advancements in technology and research have led to improved efficacy and safety of these treatments, enhancing patient outcomes and contributing to their rising adoption. Furthermore, growing public and private investments, as well as supportive government initiatives, have fueled innovation in this sector, paving the way for new therapies and expanded manufacturing capabilities within the US.

    Opportunities to be explored in the US market include the potential for CAR T cell therapy to extend into solid tumors, which remains an area with significant unmet medical needs. Collaborative efforts between biotech firms and research institutions are crucial in developing next-generation therapies that could address these challenges. Additionally, personalized medicine approaches are gaining traction, which can lead to tailored CAR T cell therapies for individual patients, further expanding the market potential.

    Trends in recent times reflect an increased focus on manufacturing processes and the overall supply chain for CAR T therapies, with efforts being made to streamline and enhance production efficiency. The emergence of outpatient treatment models has enhanced patient access and experience, aligning with the broader shift towards value-based care. Moreover, regulatory bodies in the US are actively working on guidelines to expedite the approval process for these therapies, enabling quicker access for patients in need.

    The integration of digital health solutions and telemedicine is also becoming more prominent, facilitating patient engagement and follow-up care connected with CAR T cell therapies in the US market.

    Market Segment Insights

    Car T Cell Therapy Market Therapeutic Area Insights

    The US Car T Cell Therapy Market has been increasingly gaining traction within the Therapeutic Area segment, driven primarily by significant advancements in Research and Development and the mounting prevalence of various diseases. Among the notable focuses within this segment is Oncology, which encompasses a wide range of cancers that are prevalent in the United States. The effectiveness of Car T Cell Therapy in treating hematological malignancies such as certain leukemias and lymphomas has propelled its adoption significantly.

    This therapeutic approach enhances the body’s immune response against cancer cells, making it a pivotal treatment option for patients with relapsed or refractory forms of these malignancies.

    In addition to Oncology, Autoimmune Diseases represent another critical category within the US Car T Cell Therapy Market, where the potential of engineered T cells is being explored to address conditions such as rheumatoid arthritis and lupus. This area poses unique challenges, as the immune system mistakenly attacks the body’s own tissues, but emerging therapies aim to recalibrate immune responses, offering hope for improved patient outcomes. The novelty of applying T Cell Therapy in such areas underscores the dynamic nature of this market and the opportunities for innovation.

    Furthermore, Infectious Diseases represent a growing area of interest, particularly in the context of cellular therapies targeting viral infections, including HIV and hepatitis. The integration of Car T Cell Therapy in addressing the immune response to infectious agents provides new avenues for managing chronic infections that have been traditionally challenging to eradicate. As the US faces ongoing public health challenges, the application of Car T Cell Therapy in Infectious Diseases holds promise for the development of groundbreaking treatments that can significantly improve patient health.

    The US Car T Cell Therapy Market within the Therapeutic Area segment is poised for growth, driven by the increasing incidence of applicable diseases and the ongoing pursuit of new treatment modalities. Various challenges still exist, including regulatory hurdles and the complexity of manufacturing tailored therapies, yet ongoing collaborations between academic institutions and industry players are likely to enhance progress in this area. This market segment reflects a robust commitment to advancing therapeutic options that can address critical health concerns in the United States, demonstrating the potential of Car T Cell Therapy to transform treatment paradigms across several disease categories.

    Car T Cell Therapy Market Cell Source Insights

    The Cell Source segment within the US Car T Cell Therapy Market is a crucial component driving advancements in cancer treatment. The market is characterized by three primary categories Autologous, Allogeneic, and Gene-Edited cells. Autologous therapies, derived from a patient’s own T cells, often lead in acceptance due to personalized treatment approaches, while Allogeneic options offer the advantage of being more readily available and potentially reducing time to treatment. Gene-Edited cells represent an innovative frontier, promising enhanced efficacy and precision in targeting cancer cells through advanced genetic modifications.

    The growing prevalence of hematological malignancies in the US, coupled with significant investment in Research and Development, fuels innovation in this segment. Regulatory support is also pivotal, as the US Food and Drug Administration has shown commitment to streamlining approval processes for these therapies. The expanding application of CAR T cell therapies in solid tumors further underscores the importance of the Cell Source segment in the broader landscape of the US Car T Cell Therapy Market. As understanding of genetic engineering and immunotherapy deepens, these categories are expected to evolve, addressing challenges and creating opportunities within the industry.

    Car T Cell Therapy Market Indication Insights

    The US Car T Cell Therapy Market segmentation based on Indication reveals significant opportunities and highlights the therapeutic potential of this innovative treatment in addressing various hematological malignancies. Among these, Acute Lymphoblastic Leukemia (ALL) has garnered substantial attention due to its aggressive nature and prevalence in pediatric populations, prompting intensified Research and Development efforts. Non-Hodgkin Lymphoma (NHL) also represents a major focus within the market, driven by its diverse subtypes and the critical need for effective therapies for patients who have relapsed or are refractory to traditional treatments.

    Multiple Myeloma, characterized by its complex pathophysiology and increasing incidence rates, remains a significant area of concern for healthcare providers, leading to the growth of novel CAR T Cell therapies targeting this indication. The increasing awareness about the efficacy of these therapies and supportive government policies are fueling advancements, thus positioning the US Car T Cell Therapy Market as a pivotal segment within the broader biopharmaceutical industry. Overall, the advancements in CAR T Cell therapies support the market growth and signify an important shift in treatment paradigms for hematological malignancies in the United States.

    Car T Cell Therapy Market End User Insights

    The US Car T Cell Therapy Market has shown significant developments, particularly in the End User sector, which includes Hospitals, Research Institutes, and Cancer Treatment Centers. Hospitals are crucial as they provide frontline care and infrastructure for administering advanced therapies, making them a critical access point for patients. Research Institutes significantly contribute to the advancement of Car T Cell technologies, focusing on cutting-edge research and clinical trials that drive innovation in the field. They play a key role in developing new therapies and optimizing existing ones, thereby pushing the boundaries of cancer treatment.

    Cancer Treatment Centers are specialized facilities that focus exclusively on cancer care; they provide tailored treatment plans and comprehensive support, contributing to a more effective patient experience. The interplay among these various End Users enhances the overall landscape of the US Car T Cell Therapy Market by driving accessibility, innovation, and patient-centered care, ultimately leading to improved treatment outcomes and higher patient satisfaction levels. The increasing prevalence of cancer and the demand for personalized medicine are expected to further bolster these segments as they adapt to evolving therapeutic needs.

    Get more detailed insights about US CAR T Cell Therapy Market Research Report - Forecast to 2035

    Key Players and Competitive Insights

    The US Car T Cell Therapy Market has emerged as a dynamic landscape fueled by advances in immunotherapy and an increasing prevalence of cancer. As the demand for innovative cancer treatments escalates, companies are fiercely competing to establish their presence and enhance their product offerings. This market is characterized by rapid technological advancements, strategic partnerships, and a robust focus on clinical research and development. The entry of notable players has intensified competition, with companies vying for regulatory approvals and market share, which drives significant investment in research efforts aimed at refining therapies and improving patient outcomes.

    Growing awareness of the therapeutic potential of CAR T cell technology has further accelerated market growth, making it essential for companies to leverage their unique strengths while adapting to the evolving regulatory landscape.

    Legend Biotech

    Legend Biotech has carved out a significant presence within the US Car T Cell Therapy Market, showcasing its innovative approach and strong research capabilities. The company has distinguished itself through its focus on developing groundbreaking CAR T therapies with an emphasis on efficacy and safety. Leveraging substantial investments in R&D, Legend Biotech has positioned itself as a front-runner in this competitive arena, bolstered by a rigorous clinical pipeline that aims to address various types of hematological malignancies.

    Furthermore, the company's strategic collaborations with research institutions and healthcare providers have enabled it to advance its product portfolio effectively, enhancing its reputation and fostering trust within the medical community. The strength of Legend Biotech lies in its commitment to improving patient outcomes through cutting-edge therapies, paving the way for enhanced treatment modalities in the fight against cancer.

    Sana Biotechnology

    Sana Biotechnology has emerged as a key player in the US Car T Cell Therapy Market, focusing on pioneering genetic engineering techniques to develop next-generation CAR T cell therapies. The company's portfolio includes various candidates that target specific cancers, reflecting a tailored approach to treatment. Sana Biotechnology's strengths lie in its innovative platform and commitment to harnessing cutting-edge technology to address unmet medical needs in oncology.

    Its presence in the market is bolstered by a series of partnerships and collaborations aimed at advancing its research initiatives, which underscores the company's strategic vision. The company also emphasizes ongoing clinical trials, which play a crucial role in validating its therapeutic candidates. The initiation of mergers and acquisitions has further enhanced Sana Biotechnology's capabilities and market access, allowing for a more comprehensive approach to developing CAR T therapies in the US. With a robust pipeline and a focus on innovation, Sana Biotechnology is positioned to make a significant impact within the competitive landscape of Car T cell therapy.

    Key Companies in the US CAR T Cell Therapy Market market include

    Industry Developments

    Recent developments in the US Car T Cell Therapy Market reflect significant advancements and strategic movements within key companies such as Legend Biotech, Bristol Myers Squibb, Novartis, and Gilead Sciences. In August 2023, Legend Biotech announced promising clinical trial results for its Car T Cell product, targeting multiple myeloma, which could potentially alter treatment protocols.

    Furthermore, Bristol Myers Squibb and Novartis have made strides in expanding their Car T Cell Therapy portfolios, enhancing competitive dynamics in the market. Notably, in September 2023, Kite Pharma, a Gilead Sciences subsidiary, garnered attention with its acquisition of a novel T Cell Therapy platform, aimed at increasing innovation and market share. This move comes in the context of a rapidly growing market valuation, projected to reach several billion dollars by 2025, driven by increasing demand for personalized therapies and advancements in manufacturing technologies.

    The US Car T Cell Therapy Sector has experienced notable events in recent years, including the approvals of several groundbreaking therapies by the FDA, which have established a solid foundation for future developments.

    Market Segmentation

    Car T Cell Therapy Market End User Outlook

    • Hospitals
    • Research Institutes
    • Cancer Treatment Centers

    Car T Cell Therapy Market Indication Outlook

    • Acute Lymphoblastic Leukemia
    • Non-Hodgkin Lymphoma
    • Multiple Myeloma

    Car T Cell Therapy Market Cell Source Outlook

    • Autologous
    • Allogeneic
    • Gene-Edited

    Car T Cell Therapy Market Therapeutic Area Outlook

    • Oncology
    • Autoimmune Diseases
    • Infectious Diseases

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 1.68(USD Billion)
    MARKET SIZE 2024 2.0(USD Billion)
    MARKET SIZE 2035 10.0(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 15.756% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2023
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Legend Biotech, Sana Biotechnology, Bristol Myers Squibb, Novartis, Celgene, Kite Pharma, Fate Therapeutics, Gilead Sciences, Adaptimmune, CureVac, CART T Cell Therapies, Amgen, Bioxcel Therapeutics, Juno Therapeutics, Celyad Oncology
    SEGMENTS COVERED Therapeutic Area, Cell Source, Indication, End User
    KEY MARKET OPPORTUNITIES Increased lymphoma and leukemia cases, Expansion into solid tumors, Development of off-the-shelf therapies, Enhanced manufacturing processes, Strategic partnerships and collaborations
    KEY MARKET DYNAMICS rapid technological advancements, increasing cancer prevalence, high healthcare expenditure, significant R&D investments, emerging competitive landscape
    COUNTRIES COVERED US

    FAQs

    What is the expected market size of the US Car T Cell Therapy Market in 2024?

    The US Car T Cell Therapy Market is expected to be valued at 2.0 billion USD in 2024.

    What is the projected market size of the US Car T Cell Therapy Market by 2035?

    By 2035, the US Car T Cell Therapy Market is projected to reach a value of 10.0 billion USD.

    What is the forecasted CAGR for the US Car T Cell Therapy Market from 2025 to 2035?

    The US Car T Cell Therapy Market is expected to grow at a CAGR of 15.756% from 2025 to 2035.

    Which therapeutic area will dominate the US Car T Cell Therapy Market by 2035?

    Oncology is projected to dominate the US Car T Cell Therapy Market, reaching a value of 6.0 billion USD by 2035.

    What will be the market value of Autoimmune Diseases in the US Car T Cell Therapy Market by 2035?

    The market value for Autoimmune Diseases in the US Car T Cell Therapy Market is expected to be 2.5 billion USD by 2035.

    Which major players are actively involved in the US Car T Cell Therapy Market?

    Key players in the US Car T Cell Therapy Market include Bristol Myers Squibb, Novartis, and Gilead Sciences.

    How will the market for Infectious Diseases in the US Car T Cell Therapy Market evolve by 2035?

    The market for Infectious Diseases in the US Car T Cell Therapy Market is anticipated to reach 1.5 billion USD by 2035.

    What key trends are influencing the growth of the US Car T Cell Therapy Market?

    Emerging trends in the market include advancements in technology and increased investment in cancer therapies.

    What challenges might impact the growth of the US Car T Cell Therapy Market?

    Challenges include regulatory hurdles and the high cost associated with Car T Cell therapies.

    How is the market expected to grow in the oncology segment by 2035?

    The oncology segment of the US Car T Cell Therapy Market is expected to grow significantly, from 1.2 billion USD in 2024 to 6.0 billion USD by 2035.

    What will be the market value of the US Car T Cell Therapy Market by 2035?

    By 2035, the market is projected to reach a value of 11.0 billion USD.

    What is the expected CAGR for the US Car T Cell Therapy Market from 2025 to 2035?

    The market is anticipated to grow at a CAGR of 16.763% during the forecast period from 2025 to 2035.

    What is the projected market size for the Oncology segment of the US Car T Cell Therapy Market in 2035?

    The Oncology segment is expected to reach 6.0 billion USD in market size by 2035.

    Which companies are key players in the US Car T Cell Therapy Market?

    Major players in the market include Legend Biotech, Bristol Myers Squibb, Novartis, and Gilead Sciences, among others.

    What is the expected market valuation for Autoimmune Diseases in the US Car T Cell Therapy Market in 2035?

    The market for Autoimmune Diseases is expected to be valued at 3.0 billion USD by 2035.

    How much is the US Car T Cell Therapy Market for Infectious Diseases projected to be in 2024?

    In 2024, the market for Infectious Diseases is projected to be valued at 0.4 billion USD.

    What are the growth opportunities within the US Car T Cell Therapy Market?

    There are significant growth opportunities in oncology, autoimmune disorders, and the expanding use of personalized therapies.

    What are the main applications of Car T Cell Therapy in the US market?

    The primary applications include treatment for oncology, autoimmune diseases, and infectious diseases.

    How does the growth rate of the US Car T Cell Therapy Market compare across different therapeutic areas?

    The growth rate is particularly strong in oncology, where the market is projected to expand significantly by 2035.

    US CAR T Cell Therapy Market Research Report - Forecast to 2035 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Stories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study
    Chemicals and Materials